About REXAHN

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing the next generation of targeted therapeutics for the treatment of cancer.
Rexahn's clinical development programs target specific proteins that are selectively localized in human cancer cells and not in healthy tissues resulting in increased efficacy and reduced toxicity.


News

Rexahn Receives FDA Orphan Drug Designation for RX-3117 in Treatment of Pancreatic Cancer


Rexahn Pharmaceuticals to Present at the 14th Annual Biotech in Europe Investor Forum for Global Partnering and Investment in Basel, Switzerland


More


Portfolio